PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while CRVO stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Negative gross profit growth while CRVO is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
5.53%
EBIT growth below 50% of CRVO's 18.17%. Michael Burry would suspect deeper competitive or cost structure issues.
5.53%
Operating income growth under 50% of CRVO's 18.17%. Michael Burry would be concerned about deeper cost or sales issues.
5.62%
Net income growth under 50% of CRVO's 18.65%. Michael Burry would suspect the firm is falling well behind a key competitor.
13.79%
EPS growth under 50% of CRVO's 34.12%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.79%
Diluted EPS growth under 50% of CRVO's 34.12%. Michael Burry would worry about an eroding competitive position or excessive dilution.
10.10%
Share reduction more than 1.5x CRVO's 23.52%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
10.10%
Diluted share reduction more than 1.5x CRVO's 23.52%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth at 50-75% of CRVO's 35.72%. Martin Whitman would question if the firm lags in monetizing sales effectively.
17.73%
FCF growth under 50% of CRVO's 35.72%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Negative 10Y OCF/share CAGR while CRVO stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
94.36%
5Y OCF/share CAGR is similar to CRVO's 99.22%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
80.21%
3Y OCF/share CAGR at 75-90% of CRVO's 95.67%. Bill Ackman would press for improvements in margin or overhead to catch up.
-551.14%
Negative 10Y net income/share CAGR while CRVO is at 99.99%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.20%
5Y net income/share CAGR similar to CRVO's 99.33%. Walter Schloss might see both on parallel mid-term trajectories.
81.22%
3Y net income/share CAGR 75-90% of CRVO's 95.48%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
1992.70%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-67.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-15.48%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
We cut SG&A while CRVO invests at 5.35%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.